PRME - NASDAQ
Prime Medicine, Inc.
$3.14
-2.2%Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotPrime Medicine, Inc. Management Team
Dr. Jeremy S. Duffield M.D., Ph.D.
Chief Scientific Officer
Compensation
$785,544
Prime Medicine, Inc. Insider Positioning
During the last 12 months, insiders have purchased $35.84M worth of PRME shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
10.9M
35.84M
0
0.00
+35.8M
+$35.84M
Top Buyers
Nelsen Robert
Director, 10 Percent Owner:
$10.00M
Arch Venture Partners Xii, Llc
10 Percent Owner
$10.00M
Arch Venture Partners X, Llc
10 Percent Owner
$10.00M
Gv 2021 Gp, L.L.C.
10 Percent Owner
$4.95M
Lee Ann L.
Officer: Chief Technical Officer
$731K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $35.84M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
PRME - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | July 14, 2025 | August 01, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 22, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 12, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 14, 2023 | 2023 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.